Increased levels of sCD171 have been detected in the plasma of cancer patients and correlated with disease progression or prognosis in patients with gastrointestinal stromal tumors [41], breast cancer [42], and glioblastoma [43], suggesting the potential of CD171 as a noninvasive circulating tumor biomarker. Here, L1CAM is linked to gastrointestinal stromal tumor.